PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
AUTH/3174/3/19 Otsuka

Anonymous Employees v Otsuka Europe (AUTH/3174/3/19): Disguised promotion at congress and internal β€œdon’t complain” messaging

Otsuka Europe misclassified a promotional congress symposium as non-promotional (disguised promotion) and a senior employee’s internal comments were found to undermine whistleblowing…

2019
CASE
AUTH/3186/5/19 Almirall ⭐ Case of the Week

AUTH/3186/5/19: Anonymous v Almirall β€” Berlin psoriasis meeting arrangements (no breach)

Anonymous ex-employee alleged UK doctors were invited to a β€œlavish” Berlin meeting based on prescribing and that hospitality/entertainment breached the Code. Panel…

2019
CASE
AUTH/3154/2/19 Dr Falk Pharma

Dr Falk Pharma: website product pages and external links lacked compliant prescribing information (AUTH/3154/2/19)

Complaint upheld in part: Dr Falk Pharma’s HCP website pages (and a linked historical ad) lacked compliant prescribing information; a Jorveza media…

2018
CASE
AUTH/3108/10/18 Mitsubishi Tanabe Pharma

AUTH/3108/10/18: Mitsubishi Tanabe Pharma Europe website ruled to promote POMs to the public

Mitsubishi Tanabe’s corporate products pages for Exembol (argatroban) and Tanatril were accessible to the public and included product claims/indications without clear audience…

2010
CASE
AUTH/2355/9/10 Takeda

Takeda website β€˜What’s New’ link and press release for Mepact ruled promotional to the public (AUTH/2355/9/10)

Takeda’s homepage headline β€œNICE says no to life saving treatment…” linked to a Mepact press release with emotive survival claims. PMCPA ruled…

2010
CASE
AUTH/2377/12/10 Merck Sharp & Dohme

MSD Janumet e-detail: β€œhelps more patients get to goal” ruled a hanging comparison and subgroup data was over-emphasised (AUTH/2377/12/10)

Novo Nordisk challenged a Janumet e-detail headline and a prominent 1.8% HbA1c subgroup result. PMCPA ruled the headline was a hanging comparison,…

2011
CASE
AUTH/2398/4/11 Norgine ⭐ Case of the Week

AUTH/2398/4/11: Director/Shire v Norgine – Movicol Paediatric Plain β€˜NICE recommends… FIRST-LINE’ campaign (No breach)

Shire challenged Norgine’s β€˜NICE recommends MOVICOL Paediatric Plain FIRST-LINE’ ad/leavepiece as unauthorised, unreferenced and implying off-label paediatric use. PMCPA ruled no breach…

2011
CASE
AUTH/2390/2/11 Alcon Laboratories

AUTH/2390/2/11: Anonymous representative v Alcon β€” Azarga pH demonstration (No breach)

Anonymous complaint alleged reps used litmus paper and eye drops to demonstrate pH and encouraged instillation into eyes. Panel found no evidence…

2018
CASE
AUTH/3093/9/18 Roche Products

AUTH/3093/9/18: Director v Roche β€” Clinical trial disclosure (No breach)

BMJ analysis suggested Roche had 15 due EUCTR trials without posted results. Panel found 14 had no UK nexus and 1 UK-site…

2011
CASE
AUTH/2403/5/11 Boehringer Ingelheim

Boehringer Ingelheim press release on Pradaxa: ruled unbalanced for omitting bleeding risk (AUTH/2403/5/11)

A GP complained about a Daily Mail article on Pradaxa. PMCPA assessed BI’s press release (not the article) and ruled it breached…

2011
CASE
AUTH/2436/9/11 Shire Pharmaceuticals

AUTH/2436/9/11: Genzyme v Shire β€” VPRIV website claims (misleading comparative efficacy and manufacturing risk statements)

Shire’s VPRIV website was ruled misleading for β€œat least as effective as” (non-inferiority data), β€œdoes not require gene manipulation”, and β€œminimising the…

2018
CASE
AUTH/3119/11/18 Pfizer ⭐ Case of the Week

AUTH/3119/11/18: Director v Pfizer β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3119/11/18 (Director v Pfizer) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2018
CASE
AUTH/3099/9/18 Allergan

AUTH/3099/9/18: Director v Allergan β€” late posting of clinical trial results on EUCTR

PMCPA took up a BMJ analysis of EUCTR reporting. Allergan was found in breach of Clause 9.1 for late EUCTR results posting…

2012
CASE
AUTH/2517/6/12 ProStrakan

AUTH/2517/6/12: Anonymous v ProStrakan – Adcal-D3 Caplet promotion and sales briefing (Clause 15.9 breach)

Anonymous complaint alleged misleading trial claims and a β€œswitch programme” for Adcal-D3 Caplet. Panel found no breach for promo materials or therapy…

2012
CASE
AUTH/2497/4/12 Vifor Pharma

AUTH/2497/4/12: Pharmacosmos v Vifor β€” competitor dosing information (Monofer) (No breach)

Pharmacosmos alleged Vifor reps misled HCPs that Monofer total dose infusion had a 1,000mg max. Panel found evidence insufficient on balance of…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training